Historical record - last NADAC effective date: 1/2/2015
Product Information
ZYCLARA 3.75% CREAM is a brand product labeled by Bausch Health US LLC, priced at $36.0836 per EA under NDC 99207027028. Its NADAC has been published 112 times since Nov 28, 2013.
FDA first approved this application on Mar 25, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
37.5 mg/g
Manufacturer
Bausch Health US LLCNDC
99207027028
Classification
Brand
Dosage Form
CREAM
Route
TOPICAL
Effective Date
1/2/2015
Active Ingredients
IMIQUIMODApproval Type
New Drug (NDA)
FDA Application
NDA022483FDA Approved
3/25/2010
TE Code
AB
On Market Since
11/28/2011
Pharmacological Classes
Price Statistics
The NADAC for ZYCLARA 3.75% CREAM has been published 112 times since Nov 28, 2013, and over the history we have for it it has risen 32.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $36.0836 per EA |
|---|---|
| All-time high | $36.0836 (Jan 13, 2016) |
| All-time low | $27.2844 (Nov 28, 2013) |
| Median price | $31.3770 |
| Average price | $33.3485 |
| Largest weekly change | +15.0% (Jan 15, 2014) |
| Weeks tracked | 112 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+32.2%
Last surveyed Jan 13, 2016 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the imiquimod market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bausch Health US LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
imiquimod market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZYCLARA 3.75% CREAM?
The current National Average Drug Acquisition Cost (NADAC) for ZYCLARA 3.75% CREAM, manufactured by Bausch Health US LLC, is $36.0836 per EA (NDC 99207027028), effective Jan 13, 2016.
How has the price of ZYCLARA 3.75% CREAM changed over time?
Over the history we have for it, the NADAC for ZYCLARA 3.75% CREAM has risen 32.2%. It has been tracked across 112 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ZYCLARA 3.75% CREAM?
Since Nov 28, 2013, the NADAC for ZYCLARA 3.75% CREAM has ranged from a low of $27.2844 (Nov 28, 2013) to a high of $36.0836 (Jan 13, 2016), with a median of $31.3770 per EA.
Are there cheaper alternatives to ZYCLARA 3.75% CREAM?
No other NADAC-published product currently shares the active ingredient and strength of ZYCLARA 3.75% CREAM in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ZYCLARA 3.75% CREAM?
ZYCLARA 3.75% CREAM (NDC 99207027028) is labeled by Bausch Health US LLC, and CMS classifies it as a brand product.